Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authorsde Boer, Pieter T
van Lier, Alies
de Melker, Hester
van Wijck, Albert J M
Wilschut, Jan C
van Hoek, Albert Jan
Postma, Maarten J
MetadataShow full item record
TitleCost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines.
Published inBMC Med 2018; 16(1):228
- Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
- Authors: Le P, Rothberg MB
- Issue date: 2018 Feb 1
- Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
- Authors: Grupping K, Campora L, Douha M, Heineman TC, Klein NP, Lal H, Peterson J, Vastiau I, Oostvogels L
- Issue date: 2017 Dec 12
- Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
- Authors: Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, von Krempelhuber A, Anastassopoulou A
- Issue date: 2017 Oct 3
- Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States.
- Authors: Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, Hicks K, Lee B, Yawn B
- Issue date: 2018 Aug 9
- Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
- Authors: de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ
- Issue date: 2013 Feb 18
Showing items related by title, author, creator and subject.
Immune Responses After 2 Versus 3 Doses of HPV Vaccination up to 4½ Years After Vaccination: An Observational Study Among Dutch Routinely Vaccinated Girls.Donken, Robine; Schurink-Van't Klooster, Tessa M; Schepp, Rutger M; van der Klis, Fiona R M; Knol, Mirjam J; Meijer, Chris J L M; de Melker, Hester E (2017-02-01)In 2014 the Netherlands switched from 3 to 2 doses for routine vaccination with the prophylactic bivalent human papillomavirus (HPV) vaccine. The current study explored whether antibody responses are noninferior after 2 versus 3 doses in girls.
Effect of the bivalent HPV vaccine on viral load of vaccine and non-vaccine HPV types in incident clearing and persistent infections in young Dutch females.van der Weele, Pascal; Breeuwsma, Martijn; Donken, Robine; van Logchem, Elske; van Marm-Wattimena, Naomi; de Melker, Hester; Meijer, Chris J L M; King, Audrey J (2019-01-01)HPV vaccination with the bivalent vaccine is efficacious against HPV16 and 18 infections and cross-protection against non-vaccine HPV types has been demonstrated. Here, we assessed (cross-) protective effects of the bivalent HPV16/18 vaccine on incident and persistent infections and viral load (VL) of fifteen HPV types in an observational cohort study monitoring HPV vaccine effects. Vaginal samples were obtained annually. Type-specific VL assays were developed for HPV6,11,31 33,35,39,45,51,52,56,58,59 and 66 and used in addition to existing HPV16 and 18 assays. Rate differences of incident clearing and persistent infections were correlated with differences in VL and vaccination status. HPV16/18 vaccination resulted in significantly lower incidence of HPV16/18 infections and significantly lower VL in breakthrough HPV16 (p<0.01) and 18 infections (p<0.01). The effects of vaccination on non-vaccine type VL were ambiguous. Incidence and/or persistence rates of HPV31, 33, 35 and 45 were reduced in the vaccinated group. However, no significant type specific VL effects were found against HPV31, 33, 45, 52 in the vaccinated group. For HPV 6, 59 and 66 no significant reductions in numbers of incident and persistent infections were found, however borderline) VL reductions following vaccination were observed for HPV6 (p = 0.01), 59 (p = 0.10) and 66 (p = 0.03), suggesting a minor effect of the vaccine on the VL level of these HPV types. Overall, vaccination resulted in infections with slightly lower VL, irrespective of HPV type. In conclusion, vaccination with the bivalent HPV16/18 vaccine results in significantly reduced numbers of HPV16 and 18 incidence rates and reduced VL in breakthrough infections. Significant reductions in incident and/or persistent HPV31, 33, 35 and 45 infections were found, but no significant effect was observed on the VL for infections with these types. For the other non-vaccine HPV types no reduction in incident and/or persistent infections were found, but overall the VL tended to be somewhat lower in vaccinated women.
Differences by sex in IgG levels following infant and childhood vaccinations: An individual participant data meta-analysis of vaccination studies.Boef, Anna G C; van der Klis, Fiona R M; Berbers, Guy A M; Buisman, Anne-Marie; Sanders, Elisabeth A M; Kemmeren, Jeanet M; van der Ende, Arie; de Melker, Hester E; Rots, Nynke Y; Knol, Mirjam J (2018-01-08)If immune responses to vaccination differ between males and females, sex-specific vaccination schedules may be indicated. We systematically reanalysed childhood vaccination studies conducted in The Netherlands for sex-differences in IgG-responses. To assess the impact of potential sex-differences in IgG-responses, we explored sex-differences in vaccine failure/effectiveness and reactogenicity.